Absorption of new HIV‐1 protease inhibitor, KNI‐272, after intraduodenal and intragastric administrations to rats: Effect of solvent

Biopharmaceutics & Drug Disposition

Volumn 16, Issue 4, 1995, Pages 269-277

  Sugahara, M ^a   Kiriyama, A ^a   Hamada, Y ^a   Kiso, Y ^a   Takada, K ^a  

^a KYOTO PHARMACEUTICAL UNIVERSITY   (Japan)

Author keywords

absorption; anti AIDS drug; bioavailability; HIV 1 protease inhibitor; KNI 272; rat

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTIVIRUS AGENT; CASTOR OIL; KYNOSTATIN 272; POLYSORBATE 80; PROPYLENE GLYCOL; PROTEINASE INHIBITOR; RICINOMACROGOL; SOLVENT; SURFACTANT; WATER;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG SOLUBILITY; GASTROINTESTINAL ABSORPTION; HUMAN IMMUNODEFICIENCY VIRUS 1; INTRAGASTRIC DRUG ADMINISTRATION; MALE; NONHUMAN; RAT;

ADMINISTRATION, ORAL; ANIMAL; BIOLOGICAL AVAILABILITY; HIV PROTEASE INHIBITORS; HIV-1; INTESTINAL ABSORPTION; KINETICS; MALE; OLIGOPEPTIDES; RATS; RATS, WISTAR; SOLVENTS; TIME FACTORS;

EID: 0029063841     PISSN: 01422782     EISSN: 1099081X     Source Type: Journal    
DOI: 10.1002/bdd.2510160403     Document Type: Article

References (16)

1. Human immunodeficiency virus protease: a target for AIDS therapy
2. Anti‐AIDS drug development: challenges and strategies
3. The HIV‐1 protease as a therapeutic target for AIDS
4. Renin inhibitors
5. Design and synthesis of HIV protease inhibitor containing a hydroxymethylcarbonyl‐isostere as a transition state mimic
6. In vitro anti‐human immunodeficiency virus (HIV) activities of transition state mimetric HIV protease inhibitors containing allophenylnorstatine
7. Plasma pharmacokinetics and urinary and biliary excretion of a new potent tripeptide HIV‐1 protease inhibitor, KNI‐272, in rats after intravenous administration
8. Pharmacokinetics of FK‐506, a novel immunosuppressant, after intravenous and oral administrations to rats
9. Comparison of a new orally potent tripeptide HIV‐1 protease inhibitor (anti‐AIDS drug) based on pharmacokinetic characteristics in rats after intravenous and intraduodenal administrations
10. Pharmacokinetics and safety of enalkiren (ABBOTT‐64662) following oral and intravenous doses in normal subjects
11. Pharmacological investigations of a new renin inhibitor in normal sodium‐unrestricted volunteers
12. The achievement of a well absorbed, efficacious renin inhibitor
13. Ro 31–8959/003
14. 2 symmetric inhibitors of the human immunodeficiency virus type 1 protease
15. Biological and pharmaceutical factors affecting and absorption and lymphatic delivery of cyclosporin A from gastrointestinal tract